Anlotinib induced type 1 diabetes: a case report
Studies have shown some tyrosine kinase inhibitors (TKIs) can influence glucose metabolism leading to either hypoglycemia or hyperglycemia which is reversable in most patients after treatment cessation. Anlotinib is a novel oral multi-target tyrosine kinase inhibitor (TKI) which has been approved fo...
Saved in:
| Main Authors: | Jing Chen, Daohan Xia, Linqiu Ke |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1508645/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of anlotinib monotherapy for advanced hepatocellular carcinoma and clinical role of α-fetoprotein
by: Jianping Chang, et al.
Published: (2025-08-01) -
Anlotinib combined with penpulimab in the treatment of advanced adult thoracic spinal osteosarcoma: a case report
by: Xiaochun Chen, et al.
Published: (2025-07-01) -
Case Report: Severe brigatinib-induced pneumonitis in a patient with EML4–ALK+ metastatic non-small cell lung adenocarcinoma
by: Khyati Somayaji Dasika, et al.
Published: (2025-04-01) -
Treatment of Chronic Myeloid Leukemia According to Current Guidelines: The Results of the Pilot Prospective Study “Early Induction Therapy and Monitoring” (РИТМ)
by: OA Shukhovv, et al.
Published: (2019-03-01) -
Efficacy of Anlotinib Plus Docetaxel in Advanced NSCLC Previously Treated with Platinum-Based Chemotherapy: A Systematic Review and Meta-Analysis
by: Helal F. Hetta, et al.
Published: (2025-04-01)